Islay Capital Management LLC Purchases 1,845 Shares of Cencora, Inc. $COR

Posted by Stanley Muller on Jun 16th, 2026

Islay Capital Management LLC grew its position in shares of Cencora, Inc. (NYSE:COR – Free Report) by 30.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,987 shares of the company’s stock after buying an additional 1,845 shares during the quarter. Cencora makes up about 1.6% of Islay Capital Management LLC’s investment portfolio, making the stock its 20th biggest position. Islay Capital Management LLC’s holdings in Cencora were worth $2,698,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. AustralianSuper Pty Ltd acquired a new position in shares of Cencora during the third quarter worth approximately $26,191,000. Chilton Investment Co. Inc. acquired a new position in shares of Cencora during the third quarter worth approximately $459,000. Lansforsakringar Fondforvaltning AB publ lifted its position in shares of Cencora by 5.4% during the third quarter. Lansforsakringar Fondforvaltning AB publ now owns 60,254 shares of the company’s stock worth $18,831,000 after purchasing an additional 3,073 shares in the last quarter. Nordea Investment Management AB lifted its position in shares of Cencora by 3.8% during the fourth quarter. Nordea Investment Management AB now owns 1,256,356 shares of the company’s stock worth $426,715,000 after purchasing an additional 45,712 shares in the last quarter. Finally, Assetmark Inc. lifted its position in shares of Cencora by 57.0% during the fourth quarter. Assetmark Inc. now owns 67,281 shares of the company’s stock worth $22,724,000 after purchasing an additional 24,431 shares in the last quarter. 97.52% of the stock is owned by institutional investors.

Cencora Stock Down 0.0%

Shares of NYSE:COR opened at $281.58 on Tuesday. Cencora, Inc. has a 52 week low of $244.82 and a 52 week high of $377.54. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95. The company has a market capitalization of $54.78 billion, a PE ratio of 21.59, a PEG ratio of 1.52 and a beta of 0.59. The company has a 50 day moving average price of $288.36 and a two-hundred day moving average price of $326.67.

Cencora (NYSE:COR – Get Free Report) last issued its earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The firm had revenue of $78.36 billion during the quarter, compared to the consensus estimate of $81.09 billion. During the same period in the previous year, the company posted $4.42 EPS. The firm’s revenue for the quarter was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Analysts forecast that Cencora, Inc. will post 17.79 earnings per share for the current year.

Cencora announced that its Board of Directors has initiated a stock buyback program on Thursday, May 21st that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the company to buy up to 3.9% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s leadership believes its shares are undervalued.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were paid a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend was Friday, May 15th. Cencora’s dividend payout ratio is presently 18.40%.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. UBS Group upped their target price on shares of Cencora from $410.00 to $412.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Leerink Partners restated an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. Wells Fargo & Company cut their price objective on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a report on Monday, May 11th. Citigroup cut their price objective on shares of Cencora from $405.00 to $355.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Finally, Robert W. Baird cut their price objective on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Twelve analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $374.00.

View Our Latest Analysis on Cencora

Cencora Company Profile

(Free Report)

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.